By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Life Care NewsLife Care NewsLife Care News
  • Home
  • Business
    • Business
  • News
  • Tech
  • Entertainment
  • Health
  • Education
  • Automobile
  • Sports
Search
Technology
  • Advertise
  • Advertise
Health
Entertainment
  • Home
  • Business
    • Business
  • News
  • Tech
  • Entertainment
  • Health
  • Education
  • Automobile
  • Sports
  • Advertise
  • Advertise
Copyright © 2015 - 2024 LifeCareNews Network. All Rights Reserved.
LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283
Reading: Biomea Fusion to Host Conference Call to Announce Topline Results from Phase II COVALENT-111 Study in Patients with Type 2 Diabetes (T2D)
Share
Notification Show More
Font ResizerAa
Life Care NewsLife Care News
Font ResizerAa
  • Education
  • Automobile
  • Entertainment
  • News
  • Tech
  • Sports
Search
  • Home
  • Home
    • Home 1
    • Default Home 5
  • Categories
  • Categories
    • Tech
    • Entertainment
    • Automobile
    • Sports
    • Education
    • News
    • Health
  • Bookmarks
  • Bookmarks
  • More Foxiz
    • Sitemap
  • More Foxiz
    • Sitemap
Follow US
  • Advertise
  • Advertise
Copyright © 2015 - 2024 LifeCareNews Network. All Rights Reserved. LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283
Health

Biomea Fusion to Host Conference Call to Announce Topline Results from Phase II COVALENT-111 Study in Patients with Type 2 Diabetes (T2D)

GlobeNews Wire
Last updated: 17/12/2024 11:55 AM
GlobeNews Wire
Share
2 Min Read
Biomea Fusion to Host Conference Call to Announce Topline Results from Phase II COVALENT-111 Study in Patients with Type 2 Diabetes (T2D)
SHARE
Biomea Fusion to Host Conference Call to Announce Topline Results from Phase II COVALENT-111 Study in Patients with Type 2 Diabetes (T2D)

Tuesday, December 17, 2024 at 8:00 am EST

December 16, 2024 18:15 ET  | Source: Biomea Fusion, Inc.

REDWOOD CITY, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) — Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to treat and improve the lives of patients with diabetes, obesity, and genetically defined cancers, today announced that it will host a conference call and webcast on Tuesday, December 17, 2024 at 8:00 am EST to present topline results from COVALENT-111, the company’s Phase II trial of icovamenib in patients with type 2 diabetes.

Conference Call and Webcast Details 
Webcast of Biomea’s investor update on Tuesday, December 17, 2024, at 8:00 am EST will be available to registered attendees under the Investors and Media section of the company’s website at https://investors.biomeafusion.com/news-events/events. A replay of the presentation will be archived on Biomea’s site following the event. 

About Biomea Fusion
Biomea Fusion is a clinical-stage biopharmaceutical company focused on the discovery and development of oral covalent small molecules to improve the lives of patients with diabetes, obesity, and genetically defined cancers. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein and offers a number of potential advantages over conventional non-covalent drugs, including greater target selectivity, lower drug exposure, and the ability to drive a deeper, more durable response.

We are utilizing our proprietary FUSION™ System to discover, design and develop a pipeline of next-generation covalent-binding small-molecule medicines designed to maximize clinical benefit for patients. We aim to have an outsized impact on the treatment of disease for the patients we serve. We aim to cure.

Visit us at biomeafusion.com and follow us on LinkedIn, X and Facebook. 

Contact:
Ramses Erdtmann
COO & President of Biomea Fusion 
re@biomeafusion.com

You Might Also Like

KAUST Professor Carlos Duarte Wins Prestigious Japan Prize for Pioneering Marine Science Research

BCHMiner membership exceeds 5 million, providing better mining solutions for new and old users

Exicure, Inc. (Nasdaq: XCUR) Nears Completion of Phase 2 Study of GPC-100 in Multiple Myeloma

BlackRock Canada Announces Final November Cash Distributions for the iShares Premium Money Market ETF

Acurx Announces Publication of Nonclinical In Vivo Data Differentiating Ibezapolstat’s Gut Microbiome Effects from Other Anti-CDI Antibiotics

TAGGED:Adventureannouncebiomeabiomeasbiopharmaceuticalbmeacalifcallcityclinicalstagecompanycompanysconferencecovalentcovalent-111decdecemberdedicateddiabetesdiscoveringestfusionglobehostincnasdaqnewswirepatientsphaseredwoodsourcestudytoplinetuesdaytypeuncategorizedwebcastwill

Sign Up For Daily Newsletter

Be keep up! Get the latest breaking news delivered straight to your inbox.

By signing up, you agree to our Terms of Use and acknowledge the data practices in our Privacy Policy. You may unsubscribe at any time.
Share This Article
Facebook Twitter Copy Link Print
Share
Previous Article Reviva Announces Proposed Public Offering Reviva Announces Proposed Public Offering
Next Article Harris Dental Unveils Cutting-Edge Technologies to Revolutionize Patient Care Harris Dental Unveils Cutting-Edge Technologies to Revolutionize Patient Care

Stay Connected

FacebookLike
TwitterFollow
PinterestPin
InstagramFollow
YoutubeSubscribe
Google NewsFollow
LinkedInFollow
MediumFollow
- Advertisement -

Latest News

PeterMD Announces Official Website Update Featuring Telemedicine Services for Men’s Hormone Health and TRT Support
PeterMD Announces Official Website Update Featuring Telemedicine Services for Men’s Hormone Health and TRT Support
Health 10/06/2025
Bexorg Announces Research Collaboration with Biohaven Leveraging Its Novel AI-Driven Whole-Brain Discovery Platform to Enhance CNS Drug Development
Bexorg Announces Research Collaboration with Biohaven Leveraging Its Novel AI-Driven Whole-Brain Discovery Platform to Enhance CNS Drug Development
Health 10/06/2025
MiNK Therapeutics Announces Virtual Annual Shareholders Meeting
MiNK Therapeutics Announces Virtual Annual Shareholders Meeting
Health 10/06/2025
LifeLabs Supports Communities Impacted by Saskatchewan Wildfires with ,000 Donation
LifeLabs Supports Communities Impacted by Saskatchewan Wildfires with $15,000 Donation
Health 10/06/2025
//

We increase the awareness of millions of users through our news networks. We are one of the most trusted news networks in the world.

Quick Link

  • About Us
  • Contact Us
  • Editorial Guidelines
  • Privacy Policy
  • Terms and Conditions

Top Categories

  • Automobile
  • Education
  • Entertainment
  • Health
  • News
  • Sports
  • Tech

Sign Up for Our Newsletter

Subscribe to our newsletter to get our newest articles instantly!

Life Care NewsLife Care News
Follow US
Copyright © 2015 - 2024 LifeCareNews Network. All Rights Reserved. LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283
Join Us!
Subscribe to our newsletter and never miss our latest news, podcasts etc..

Zero spam, Unsubscribe at any time.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?